Ombitasvir/paritaprevir/ritonavir + Dasabuvir + Ribavirin in HCV Genotype 1 Infected Patients Who Failed Previous Protease Inhibitor Therapy

ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Hunyady B, Abonyi M, Gerlei Z, et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clinical and Experimental Hepatology. 2018;4(2):83-90. doi:10.5114/ceh.2018.75957. APA Hunyady, B., Abonyi, M., Gerlei, Z., Gervain, J., Horváth, G., & Jancsik, V. et al. (2018). Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clinical and Experimental Hepatology, 4(2), 83-90. https://doi.org/10.5114/ceh.2018.75957 Chicago Hunyady, Béla, Margit Abonyi, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Viktor Jancsik, and Gabriella Lengyel et al. 2018. "Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy". Clinical and Experimental Hepatology 4 (2): 83-90. doi:10.5114/ceh.2018.75957. Harvard Hunyady, B., Abonyi, M., Gerlei, Z., Gervain, J., Horváth, G., Jancsik, V., Lengyel, G., Makkai, E., Pár, A., Péter, Z., Pusztay, M., Ribiczey, P., Rókusz, L., Sarrazin, C., Schneider, F., Susser, S., Szalay, F., Tornai, I., Tusnádi, A., Újhelyi, E., Werling, K., and Makara, M. (2018). Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clinical and Experimental Hepatology, 4(2), pp.83-90. https://doi.org/10.5114/ceh.2018.75957 MLA Hunyady, Béla et al. "Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy." Clinical and Experimental Hepatology, vol. 4, no. 2, 2018, pp. 83-90. doi:10.5114/ceh.2018.75957. Vancouver Hunyady B, Abonyi M, Gerlei Z, Gervain J, Horváth G, Jancsik V et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clinical and Experimental Hepatology. 2018;4(2):83-90. doi:10.5114/ceh.2018.75957.